Search

Displaying results 4451 - 4460 of 10000 in total
  1. Drug

    Pegvisomant

    go.drugbank.com/drugs/DB00082
    ApprovedInvestigational

    Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. … Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main

  2. Drug

    Zea mays pollen

    go.drugbank.com/drugs/DB10357
    Approved

    Zea mays pollen is the pollen of the Zea mays plant. Zea mays pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Twenty-Two Standardized and Non-Standardized GrassesCategories: Non-Standardized Pollen Allergenic Extract
  3. Drug

    IRX-2

    go.drugbank.com/drugs/DB05643
    Investigational

    IRX-2 contains a human leukocyte-derived cytokine mixture. It is being investigated to promote or enhance an anti-cancer immune response.

    Synonyms: Cytokine-based biologic agent IRX-2
  4. Drug

    UM-171

    go.drugbank.com/drugs/DB19449
    Investigational

    UM-171 is a pyrimidoindole derivative that is an agonist of ex vivo hematopoietic stem cell expansion and thus supports the expansion of hematopoietic stem cells.[A264868, A264873]

    Salts: UM-171 dihydrobromide dihydrateSynonyms: ((1r, 4r)-n1-(2-benzyl-7-(2-methyl-2h-tetrazol-5-yl)-9h-pyrimido(4,5-b)indol-4-yl)cyclohexane-1,4-diamine, Trans-n1-(7-(2-methyl-2h-tetrazol-5-yl)-2-(phenylmethyl)-9h-pyrimido(4,5-b)indol-4-yl)-1,4-cyclohexanediamine
  5. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks

  6. Drug

    PF-06260414

    go.drugbank.com/drugs/DB15221
    Investigational

    PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

  7. Drug

    BMS-986104

    go.drugbank.com/drugs/DB15214
    Investigational

    of BMS-986104 in Healthy Male Subjects). … BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

  8. Drug

    Caroxazone

    go.drugbank.com/drugs/DB09254
    ApprovedWithdrawn

    However, it presents a five-fold preference for the MAO-B subtype. … Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    Morphine glucuronide

    go.drugbank.com/drugs/DB06409
    Investigational

    Categories: Heterocyclic Compounds with 4 or More Rings
  10. Drug

    Bucetin

    go.drugbank.com/drugs/DB13278
    ApprovedWithdrawn

    Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]